Clinical Trial Update: A Study of a New Leishmania Vaccine Candidate ChAd63-KH [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a Leishmania vaccine candidate ChAd63-KH has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leishmaniasis Cutaneous

Drugs mentioned

• ChAd63-KH (ChAd63-KH)

Snippet

Sponsor: University of York | Conditions: Leishmaniasis, Cutaneous | Phase 2 | Status: COMPLETED